Multiple endocrine neoplasia type 1 medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:


==Medical Therapy==
==Medical Therapy==
* Medical therapy of MEN-1 includes<ref name="pmid20585352">{{cite journal |vauthors=Moyes VJ, Monson JP, Chew SL, Akker SA |title=Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism |journal=Int J Endocrinol |volume=2010 |issue= |pages=906163 |year=2010 |pmid=20585352 |pmc=2877200 |doi=10.1155/2010/906163 |url=}}</ref><ref>[http://www.niddk.nih.gov/health-information/health-topics/endocrine/multiple-endocrine-neoplasia-type-1/Pages/fact-sheet.aspx] Multiple Endocrine Neoplasia Type 1</ref><ref name="pmid2573957">{{cite journal |vauthors=Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT |title=Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study |journal=Surgery |volume=106 |issue=6 |pages=1108–17; discussion 1117–8 |year=1989 |pmid=2573957 |doi= |url=}}</ref><ref name="pmid8161665">{{cite journal |vauthors=Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT |title=Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety |journal=Aliment. Pharmacol. Ther. |volume=7 |issue=6 |pages=597–610 |year=1993 |pmid=8161665 |doi= |url=}}</ref><ref name="pmid25713781">{{cite journal |vauthors=Sadowski SM, Triponez F |title=Management of pancreatic neuroendocrine tumors in patients with MEN 1 |journal=Gland Surg |volume=4 |issue=1 |pages=63–8 |year=2015 |pmid=25713781 |pmc=4321051 |doi=10.3978/j.issn.2227-684X.2014.12.01 |url=}}</ref> 
* Because the type of pancreatic endocrine cancer associated with multiple endocrine neoplasia type 1 can be difficult to recognize, difficult to treat, and slow to progress, there are different views about the value of [[surgery]] in managing these [[tumor]]s.
* Because the type of pancreatic endocrine cancer associated with multiple endocrine neoplasia type 1 can be difficult to recognize, difficult to treat, and slow to progress, there are different views about the value of [[surgery]] in managing these [[tumor]]s.
* One approach is to "watch and wait," using medical, or nonsurgical, treatments.  According to this school of thought, pancreatic [[surgery]] has serious complications, so it should not be attempted unless it will cure a [[tumor]] or cure a [[hormone]] excess state.
* One approach is to "watch and wait," using medical, or nonsurgical, treatments.  According to this school of thought, pancreatic [[surgery]] has serious complications, so it should not be attempted unless it will cure a [[tumor]] or cure a [[hormone]] excess state.
* Excessive release of certain [[hormone]]s mainly [[gastrin]] from pancreatic endocrine cancer in multiple endocrine neoplasia type 1 needs to be treated, and [[medication]]s are often effective in blocking the effects of these [[hormone]]s.<ref>[http://www.niddk.nih.gov/health-information/health-topics/endocrine/multiple-endocrine-neoplasia-type-1/Pages/fact-sheet.aspx] Multiple Endocrine Neoplasia Type 1</ref> 
* Excessive release of certain [[hormone]]s mainly [[gastrin]] from pancreatic endocrine cancer in multiple endocrine neoplasia type 1 needs to be treated, and [[medication]]s are often effective in blocking the effects of these [[hormone]]s.
* [[Cabergoline]] is the treatment of choice for [[prolactinoma]]s.
* [[Cabergoline]] is the treatment of choice for [[prolactinoma]]s.
* [[Somatostatin]] analogues such as [[octreotide]] or [[lanreotide]] are used for the treatment of [[growth hormone]] secreting [[tumor]]s.
* [[Somatostatin]] analogues such as [[octreotide]] or [[lanreotide]] are used for the treatment of [[growth hormone]] secreting [[tumor]]s.

Revision as of 15:18, 9 October 2017

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 medical therapy

CDC on Multiple endocrine neoplasia type 1 medical therapy

Multiple endocrine neoplasia type 1 medical therapy in the news

Blogs on Multiple endocrine neoplasia type 1 medical therapy

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]

Overview

Pharmacologic medical therapies for multiple endocrine neoplasia type 1 include cabergoline, somatostatin analogues, and H2- receptor blockers.

Medical Therapy

References

  1. Moyes VJ, Monson JP, Chew SL, Akker SA (2010). "Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism". Int J Endocrinol. 2010: 906163. doi:10.1155/2010/906163. PMC 2877200. PMID 20585352.
  2. [1] Multiple Endocrine Neoplasia Type 1
  3. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT (1989). "Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study". Surgery. 106 (6): 1108–17, discussion 1117–8. PMID 2573957.
  4. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT (1993). "Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety". Aliment. Pharmacol. Ther. 7 (6): 597–610. PMID 8161665.
  5. Sadowski SM, Triponez F (2015). "Management of pancreatic neuroendocrine tumors in patients with MEN 1". Gland Surg. 4 (1): 63–8. doi:10.3978/j.issn.2227-684X.2014.12.01. PMC 4321051. PMID 25713781.

Template:WS Template:WH